The Science & The Path Forward

In 2017, a six-year-old girl named Mila Makovec was dying of Batten disease — a fatal neurodegenerative condition caused by a unique mutation in her CLN7 gene. No approved treatment existed. No clinical trial was recruiting for her specific mutation.

Dr. Timothy Yu at Boston Children’s Hospital sequenced her genome, identified the mutation (an SVA retrotransposon insertion creating a cryptic splice site), designed a splice-switching antisense oligonucleotide to correct it, tested it in her own cells, ran an accelerated toxicology study in rats, and — with FDA approval under compassionate use — administered the first dose.

Total time from mutation identification to first dose: 10 months.

Mila’s seizures dropped from ~30 per day to near zero. The drug was named milasen. It was published in the New England Journal of Medicine (Kim et al., 2019) and became the first-ever personalized antisense oligonucleotide approved for a single patient.

Since then, the n-Lorem Foundation (founded by Stanley Crooke, former CEO of Ionis Pharmaceuticals) has treated 50+ patients with personalized ASOs — free of charge, for life — with zero ASO-related serious adverse events. Other N-of-1 ASOs include atipeksen (Ataxia-Telangiectasia), jacifusen (FUS-ALS), and several unnamed programs at centers worldwide.

In the Milasen case, ASO design took months of lab work by a world-class team. We collapsed that step from months to minutes using AI trained on every known ASO-amenable gene and the full ClinVar pathogenic variant database. You tell us the gene. We identify the optimal mechanism, design candidate sequences, compute thermodynamic fitness, run off-target safety checks, and deliver a complete report with synthesis-ready sequences.

The rest of the path — synthesis, testing, regulatory filing — still requires human expertise. But it is a path with named providers, known costs, and established timelines. Not a dead end.

The ASO chemistry in your report — 2′-MOE phosphorothioate or phosphorodiamidate morpholino (PMO) — is not experimental. It is the same chemistry used in 7+ FDA-approved drugs treating thousands of patients for years. The backbone is proven. The delivery routes (intrathecal, subcutaneous) are established. The safety profile is characterized across multiple diseases and patient populations.

What is new is the sequence — the 18–25 nucleotides that target your specific gene. The platform is proven. The payload is personalized. This is analogous to how software works: once you trust the operating system, you do not re-certify it for every application.

The Right to Try Act (2018, United States) recognizes that patients with life-threatening conditions and no approved treatments have the right to access investigational therapies. Similar legislation exists in the EU, Australia, and other jurisdictions.

The Milasen precedent established that a personalized ASO can reach a patient through the single-patient compassionate-use IND pathway (21 CFR 312.310). The FDA reviewed and approved within approximately one week once safety data was submitted.

Every month a therapy sits in review is a month during which a patient with a progressive disease gets worse. The regulatory system was designed for shelf drugs serving millions. For a child with a unique mutation and no alternative, the calculus is different. The FDA has shown — repeatedly now — that it understands this.

This is computational scientific advice — the same kind of analysis that preceded every ASO drug that has ever reached a patient, performed with the same rigor, delivered in minutes instead of months, and made accessible to anyone who needs it.

This is not a drug. This is not FDA-approved therapy. This is not a substitute for medical supervision. The sequences in your report are a starting point for a process that requires professional expertise at every subsequent step.

But it is a starting point. Not a dead end. Not a wall. A door.